CytomX Therapeutics Inc CTMX:NASDAQ

Last Price$1.97NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/06/22

Today's Change+0.03(1.55%)
Bid (Size)$1.62 (2)
Ask (Size)$1.63 (7)
Day Low / High$1.94 - 2.01
Volume931.1 K
  • Latest Stories
  • Commentary and Analysis
Piper Sandler Cuts CytomX Therapeutics to Neutral From Overweight, Price Target to $1.50 From $10
5:22AM ET 7/07/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $4 to $12, according to analysts polled by Capital IQ. (MT Newswires...

Mizuho Securities Cuts CytomX Therapeutics to Neutral From Buy, Price Target to $4 From $16
5:21AM ET 7/07/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $4 to $12, according to analysts polled by Capital IQ. (MT Newswires...

--Trading in CytomX Therapeutics Shares Halted Pending News Release
4:07PM ET 7/06/2022 MT Newswires

...

CytomX Therapeutics Shares Edge Higher After BMO Capital Starts Coverage
12:57PM ET 6/24/2022 MT Newswires

CytomX Therapeutics (CTMX) shares gained more than 1% in Friday afternoon trading after BMO Capital started coverage of the company with an outperform...

BMO Capital Starts CytomX Therapeutics at Outperform With $9 Price Target
4:55AM ET 6/24/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...

Piper Sandler Adjusts Price Target on CytomX Therapeutics to $10 From $16, Reiterates Overweight Rating
5:25AM ET 5/31/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...

CytomX Therapeutics Doses First Patient in Early Trial of CX-904 to Treat Advanced Solid Tumors
9:37AM ET 5/26/2022 MT Newswires

CytomX Therapeutics (CTMX) said Thursday it has dosed the first patient in a phase 1 dose-escalation study of CX-904, a drug candidate to fight cancer...

--Wedbush Adjusts Price Target for CytomX Therapeutics to $6 From $10, Maintains Outperform Rating
2:56PM ET 5/10/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (CTMX) CYTOMX THERAPEUTICS Posts Q1 Revenue $17.1M, vs. Street Est of $21.2M
4:21PM ET 5/05/2022 MT Newswires

...

CytomX Therapeutics' 2021 Loss Widens, Revenue Declines
5:28PM ET 3/01/2022 MT Newswires

CytomX Therapeutics (CTMX) said Tuesday its 2021 net loss widened to $1.30 per share from $0.71 per share a year earlier. Analysts polled by Capital IQ...